Clal Biotech (CBI) Stock Statistics & Valuation Metrics

Clal Biotech has a market cap or net worth of ₪50.98M. The enterprise value is 69.48M.

Clal Biotech has 156,846,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Clal Biotech’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -44.02%.

The current PE Ratio of Clal Biotech is ―. Clal Biotech’s PEG ratio is 0.05.

In the last 12 months, Clal Biotech had revenue of 835.00K and earned -13.32M in profits. Earnings per share was -0.08.

In the last 12 months, operating cash flow was -5.42M and capital expenditures 0.00, giving a free cash flow of -5.42M billion.

Clal Biotech pays an annual dividend of 22.372, resulting in a dividend yield of ―

Clal Biotech upcoming earnings date is ―, ―.

Clal Biotech as a current ratio of 0.14, with Debt / Equity ratio of 78.41%

In the past 12 months, Clal Biotech has paid 0.00 in taxes.

Clal Biotech EV to EBITDA ratio is -3.21, with an EV/FCF ratio of -15.66.

Clal Biotech has ₪1.61M in cash and marketable securities with ₪18.70M in debt, giving a net cash position of -₪17.10M billion.

Gross margin is 0.00%, with operating margin of -2205.03%, and net profit margin of -1595.09%.

The average price target for Clal Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―